Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
64,967,756
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
53,828,193
-
Shares change
-
+3,900,923
-
Total reported value, excl. options
-
$240,074,209
-
Value change
-
+$12,985,182
-
Put/Call ratio
-
15%
-
Number of buys
-
54
-
Number of sells
-
39
-
Price
-
$4.46
Institutional Holders of Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) as of Q2 2024
As of 30 Jun 2024 Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) had 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 53,828,193 shares of stock of the company.
Largest 10 holders included ADAGE CAPITAL PARTNERS GP, L.L.C., Pivotal bioVenture Partners Investment Advisor LLC, Sofinnova Investments, Inc., EVENTIDE ASSET MANAGEMENT, LLC, Rock Springs Capital Management LP, SAMLYN CAPITAL, LLC, BlackRock Inc., Affinity Asset Advisors, LLC, VANGUARD GROUP INC, and FMR LLC.
This table shows 89 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.